Metastatic bladder cancer: Advances in treatment

W. M. Stadler, T. M. Kuzel*, D. Raghavan, E. Levine, N. J. Vogelzang, B. Roth, F. A. Dorr

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

At present, a combination of cisplatin, methotrexate, vinblastine and doxorubicin is the most widely used chemotherapy for metastatic bladder cancer. However, long-term follow up shows that this combination may have little effect on survival. In addition, this regimen is toxic. New agents are needed which combine efficacy with good safety profiles. Agents which have been investigated include gallium nitrate, interferon-α and paclitaxel both as single agents and in combination with established cytotoxic drugs. A number of studies have been conducted in bladder cancer with the novel nucleoside analogue, gemcitabine. Response rates of up to 33% have been recorded in two phase II studies. Gemcitabine was well tolerated in both studies with few of the side-effects normally associated with cytotoxic drugs. A third study is ongoing.

Original languageEnglish (US)
Pages (from-to)S23-S26
JournalEuropean Journal of Cancer Part A
Volume33
Issue numberSUPPL. 1
DOIs
StatePublished - Jan 1997

Keywords

  • Bladder cancer
  • Chemotherapy
  • Clinical trials
  • Gemcitabine
  • Review

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Metastatic bladder cancer: Advances in treatment'. Together they form a unique fingerprint.

Cite this